VIA Pharmaceuticals (VIAP) Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients
More News related to VIAP
- VIA Pharmaceuticals (VIAP) To Be Delisted January 4, 2010; Expects To Be Eligible For OTC Bulletin Board
- VIA Pharmaceuticals Receives Delisting Notification From NASDAQ
- VIA Pharmaceuticals, Inc. (VIAP) Receives Non-Compliance Notification From NASDAQ
- VIA Pharmaceuticals (VIAP) Receives Non-Compliance Notification From NASDAQ
- VIA Pharmaceuticals (VIAP) Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
VIA Pharmaceuticals, Inc. (Nasdaq: VIAP) announced the results of a sub-study of patients in its acute coronary syndrome (ACS) Phase 2 trial who received serial 64 slice multidetector computed tomography (MDCT) scans before and after six months of treatment with its lead drug, VIA-2291, an inhibitor of leukotrienes, proposed mediators of vascular inflammation. Results were presented in a poster session at the American Heart Association Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Annual Conference 2009 in Washington, D.C. by Jean-Claude Tardif MD, of the Montreal Heart Institute, and Dr. Rebecca Taub, VIA's Senior Vice President - Research & Development.
Subscribe to EasyStockAlerts.com & Get real-time e-mail alerts when news hits your stocks!
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
